Compare CTRI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | IMNM |
|---|---|---|
| Founded | 1909 | 2006 |
| Country | United States | United States |
| Employees | 9687 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2024 | 2020 |
| Metric | CTRI | IMNM |
|---|---|---|
| Price | $30.60 | $20.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $29.85 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 1.5M | 906.1K |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | 51.40 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $2,982,781,000.00 | $6,941,000.00 |
| Revenue This Year | $13.82 | $18.41 |
| Revenue Next Year | $8.39 | $863.23 |
| P/E Ratio | $122.40 | ★ N/A |
| Revenue Growth | ★ 13.10 | N/A |
| 52 Week Low | $14.46 | $5.15 |
| 52 Week High | $32.38 | $27.65 |
| Indicator | CTRI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 41.75 |
| Support Level | $19.76 | $18.98 |
| Resistance Level | $32.38 | $22.57 |
| Average True Range (ATR) | 1.11 | 1.10 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 77.33 | 25.75 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.